Wspólnotowy Serwis Informacyjny Badan i Rozwoju - CORDIS

FP5

ANTICANCER RETINOIDS Streszczenie raportu

Project ID: QLK3-CT-2002-02029
Źródło dofinansowania: FP5-LIFE QUALITY
Kraj: Spain

Panel of family and isotype selective retinoid modulators (agonists, partial agonists, inverse agonists, antagonists)

Known and potent, as well as novel RAR and RXR modulators (agonists, antagonists, inverse agonists&) for use in the research carried out by the Consortium members were prepared.

These benchmark retinoids are important biological tools for research.
Among the compounds prepared through ligand design and synthesis, two are particularly noteworthy:
- UVI3003, a powerful and selective RXR antagonist.
- UVI2034, a selective RAR-antagonist
Compound UVI3003 has been used in the context of RXR signalling pathways, as well as in the context of structural-activity determination.

In addition, compound UVI2003 has served as a derivative of TTNPB to show the role of the halogen at the benzoic acid end in the RARß ligand discrimination.

Kontakt

Angel DE LERA, (Professor)
Tel.: +34-986812316
Faks: +34-986811940
Adres e-mail
Śledź nas na: RSS Facebook Twitter YouTube Zarządzany przez Urząd Publikacji UE W górę